- Home
- EDIT
EDIT
Editas Medicine Inc.
as 06-20-2025 3:34pm EST
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 156.5M | IPO Year: | 2016 |
| Target Price: | $6.73 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.91 - $6.05 | Next Earning Date: | 08-06-2025 |
| Revenue: | $35,837,000 | Revenue Growth: | -48.37% |
| Revenue Growth (this year): | -60.81% | Revenue Growth (next year): | -11.66% |
Stock Insider Trading Activity of Editas Medicine Inc. (EDIT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burkly Linda | EDIT | EVP, CHIEF SCIENTIFIC OFFICER | Jun 3 '25 | Sell | $1.72 | 726 | $1,251.84 | 69,519 | |
| O'Neill Gilmore Neil | EDIT | CEO | Jun 3 '25 | Sell | $1.72 | 15,192 | $26,195.57 | 280,282 | |
| Parison Amy | EDIT | SVP, Chief Financial Officer | Jun 3 '25 | Sell | $1.72 | 446 | $768.90 | 17,506 |
Latest Editas Medicine Inc. News
EDIT Breaking Stock News: Dive into EDIT Ticker-Specific Updates for Smart Investing
Motley Fool
4 days ago
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
GlobeNewswire
9 days ago
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Zacks
10 days ago
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Motley Fool
a month ago
1 Stock Down 97% That Could Double, According to Wall Street
Pharma Voice
a month ago
A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
GlobeNewswire
a month ago
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
Simply Wall St.
a month ago
Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
a month ago
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
Compare EDIT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EDIT Editas Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.